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mice into Tg mice showed that both CD4’ and CD8+ T-cells were 
able to control the transgene expression even in the absence of 
antibody production. Results from HBsAg-Tg mice that are knock- 
out for the IFN-( receptor gene indicate that the regulation of the 
HBV envelope messenger RNA was mediated by type 1 cytokines 
produced by the activated T-lymphocytes. 
These results point to the possibility of designing more effective 
methods for the prevention and the treatment of HBV infections. 
1- Hepatitis B and &a chance for therapeutic 
peptide T-cell vaccination? 
G.K. Pape. Medical Clinic II, Klinikum Grosshadern and Institutefor 
Immunolofy, Ludwig-Maxirnilians- University, Munich, Germany 
Understanding both the immune response by which the host defends 
against hepatitis B and C virus and the mechanisms by which the 
immune response can be manipulated or modulated is a prerequisite 
for the design of novel strategies for the treatment of these viral 
diseases. With regard to both aspects we have made tremendous 
progress in recent years: T-lymphocytes are the players in the defense 
against infection. A vigorous, polyclonal, niultispecific CD8’ and 
CD4+ T-cell response is associated with viral clearance in hepatitis B 
and C. Furthermore, the virus-specific T-cell response is not only 
decisive in clearing the virus but has to be maintained to control viral 
infection. For HCV infection it has been shown that loss of the T- 
cell response leads to recurrence of HCV In patients with chronic 
viral hepatitis, the virus-specific T-cell response is absent or weak and 
more focused, a state which is called non-reactivity or ‘tolerance’ of 
T-cells. T-cells can be induced or activated by virus-specific peptides. 
Thus a principal basis of novel treatment strategies in viral hepatitis 
is the delivery and presentation of virus-specific peptides to T-cells 
of chronically infected patients in order to break their T-cell tolerance 
and successfully control the virus. 
Helicobacter pylori 
Sequencing of the Helicobacter pylori genome: 
application for knowledge of pathogenesis 
A. Labigne, P. Jenks. Insritut Pasteur, Paris, France 
In July 1997, Helicobacterpylori became the tenth bacteria to have its 
entire genome sequenced. The sequence (1.6 megabases) was pub- 
lished by The Institute for Genomic Research (TIGR), and 
represents a major resource for understanding how this organism 
colonizes the human stomach and causes gastroduodenal disease. 
Examination of the genome sequence of H. pylori has already 
identified new putative virulence factors, unraveled basic metabolic 
pathways, and provided further information on genetic organization 
and the regulation of gene expression. In the future, the genome of 
this single isolate will greatly facilitate research into specific areas of 
this bacterium’s biology, such as iron regulation, the role of recently 
identified adhesins, and the relative importance of antigenic variation 
of LPS in vivo it will also enable researchers to adopt a more global 
approach to the study of H. pylori and will allow: (1) examination of 
the genetic diversity of clinical isolates (gene polymorphism and 
diversity in genomic complement and organization); (2) charac- 
terization of differential gene expression of clinical isolates in relation 
to in vitro and in vivo conditions; (3) identification of genes essential 
for colonization of the gastric mucosa. 
Sequencing of the Helicobacter pylori genome: 
application for defining new therapeutics 
T.J. Trust. Astra Research Center Boston, MA, USA 
Knowledge of the complete genomic sequence of pathogenic 
bacteria is creating unprecedented opportunities to understand the 
pathogenesis of infectious disease and to discover new therapeutics, 
both drugs and vaccines. A genome-based strategy facilitates the 
escient identification of all antigens of a pathogen, as well as the 
rapid advanced selection of novel lethal targets not used by today’s 
antibiotics, thus providing the opportunity to identify novel classes 
of antibacterials. Helicobacter pylori is the first bacterial pathogen for 
which the complete -1.65 megabase nucleotide genome sequence of 
two isolates has been determined. O f  the -1500 H. pylori genes, 
approximately 58% have been assigned predicted function based on 
sequence similarity to a gene product of demonstrated function, 
while another 18% have homologues of unknown identity. The 
remainder have no currently identified homologues in the public data 
bases and are currently H. pylori specific. A small number of strain- 
specific genes are also present. Comparison of the two genome 
sequences has provided new insight on genomic evolution in the 
species. A number of a number of factors, including strain-specific 
genes, which could influence the clinical outcome of H. pylori 
infections have been revealed. The comparison has also identified a 
‘common set’ of H. pylori genes, which includes both novel potential 
vaccine antigens and possible drug targets for the development ofnew 
anti-H. pylori therapeutics. 
Host response to Helicobacter pylori infection: 
the ThlITh2 balance 
M.M.D. Elios, A. Amedei, G. Del Prete. Internal Medicine, CIRHel: 
University of Floreuce, Florence, Italy 
H. pylori infection represents the major cause of gastroduodenal 
disease, but only a minority of infected patients develop, throughout 
their life, gastroduodenal pathologies, like peptic ulcer, gastric cancer 
or B-cell lymphoma. The type of host immune response against H. 
pylori seems to be crucial for the outcome of the infection. 
An experimental model has been developed to investigate at clonal 
level the gastric T-cell response to H. pylori occurring in infected 
patients with uncomplicated chronic gastritis, peptic ulcer or gastric 
low-grade lyniphoma (MALToma). 
A predominant H. pylori-specific T h l  response, characterized by 
high IFN-gamma, IL-12 and TNF-alpha production, was found in 
the gastric antrum of patients with peptic ulcer. In uncomplicated 
chronic gastritis, most gastric H. pylori-specific T-cells showed com- 
bined secretion ofboth Thl -  and Th2-type cytokines (Tho profile). 
Likewise, Tho was the predominant cytokine profile of T-cells 
derived from gastric MALToma. Interestingly, however, gastric T- 
cells from MALToma, but not T-cells from chronic gastritis with or 
without ulcer, exhibited abnormal help for autologous B-cell proli- 
feration and reduced perforin- and Fas-Fas ligand-mediated killing 
of B-cells. 
These data suggest that host gastric immune response to H .  pylori 
can influence the clinical picture and that peptic ulcer may be an 
immunopathologic consequence of a T h l  -polarized response to 
some H. pylori antigens, whereas exhaustive and deregulated H. 
pylori-induced T-cell-dependent B-cell activation may support the 
onset of low-grade B-cell lymphoma. 
